Recombinant Ephb4-Hsa Fusion Protein
Stage II Bladder Urothelial Carcinoma
University of Southern Californiaprotein_peptidePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 27/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Stage II Bladder Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Recombinant Ephb4-Hsa Fusion Protein is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →